Biodistribution and dosimetry of 177Lu-labeled [DOTA 0,Tyr3]octreotate in male nude mice with human small cell lung cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 4, 2003, Pages 593-599

  Schmitt, Anneli ^a,c   Bernhardt, Peter ^a   Nilsson, Ola ^a   Ahlman, Håkan ^a   Kölby, Lars ^a   Schmitt, Jörg ^b   Forssel Aronsson, Eva ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

177Lu DOTA Tyr3 octreotate; Animal model; Biodistribution; Radionuclide therapy; Small cell lung cancer

Indexed keywords

OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSYL 3 LU 177]; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; DRUG DERIVATIVE; LUTETIUM; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE MARROW; CONFERENCE PAPER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG LABELING; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; ALGORITHM; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; METABOLISM; PATHOLOGY; RADIOTHERAPY; SMALL CELL CARCINOMA; TIME; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ALGORITHMS; ANIMALS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; HUMANS; LUTETIUM; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SOMATOSTATIN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0041335493     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322287682     Document Type: Conference Paper

References (24)

1. Reubi JC, Krenning E, Lamberts SW, Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990;37:1073.
2. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455.
3. Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion 2000;62(Suppl 1):27.
4. 1-octreotide. J Nucl Med 1995;36:7.
5. Fjälling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V, Tisell LE, Wängberg B, Nilsson O, Berg G, Michanek A, Lindstedt G, Ahlman H. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med 1996;37:1519.
6. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000;44:88.
7. Krenning EP, Kooij PPM, Pauwels S, Breeman WAP, Postema PTE, De Herder WW, Valkema R, Kwekkeboom DJ. Somatostatin receptor scintigraphy and radionuclide therapy. Digestion 1996;20:716.
8. Otte A, Jermann E, Béhé M, Goetze M, Bucher H, Roser H, Heppeler A, Mueller-Brand J, Mäcke H. DOTATOC: a powerful tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792.
9. 3-octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm 1999;14:477.
10. Otte A, Herrmann R, Heppeler A, Béhé M, Jermann E, Powell P, Mäcke H, Müller J. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439.
11. 3-octreotide (DOTATOC): A pilot study in human gliomas. Clin Cancer Res 1999;5:1025.
12. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, Halvadjieva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andreae F, Raderer M, Kurtaran A, Niederle B, Dudczak R. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50.
13. Bernhardt P, Benjegård SA, Kölby L, Johansson V, Nilsson O, Ahlman H, Forssell-Aronsson E. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiation Oncology Biol Phys 2001;51:514.
14. O'Donoghue JA, Bardies M, Wheldon TE. Relationship between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902.
15. 188Re. App Rad Isotopes 2001;55:89.
16. Reubi JC, Schär JC, Waser B, Wenger B, Heppeler A, Schmitt J, Mäcke H. Affinity profiles for human somatostatin receptor subtypes SST1-5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273.
17. Li W, Ma D, Higginbotham C, Hoffman T, Ketring A, Cutler C, Jurisson S. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol 2001;28:145.
18. 3]octreotide in patients. Eur J Nucl Med 2001;28:1319.
19. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002;32:133.
20. On-line document at: www.cancer.org American Cancer Society, Atlanta, Georgia, USA, 2002.
21. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628.
22. Loevinger R. MIRD Primer For Absorbed Dose Calculations, Society of Nuclear Medicine, 1988.
23. 177Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer 2001;94:873.
24. 1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol 2003;30:253.